Song Liu, PhD Song Liu, PhD

Song Liu

PhD

Special Interests:

Translational Bioinformatics Biomarker Discovery Companion Diagnostics Cancer Therapeutics Precision Medicine Immuno-Oncology

About Song Liu

Biography:

I graduated from the University of Science and Technology of China in 2002. I obtained my PhD from The State University of New York at Buffalo in 2006, and received the post-doctoral training at Howard Hughes Medical Institute (HHMI) at Columbia University.

I was appointed to an Assistant Professor position at Roswell Park Comprehensive Cancer Center in 2009, an Associate Professor position in 2012, and a Full Professor position in 2016.

I completed the General Management Program at the Wharton School of Business, University of Pennsylvania in 2018 (WMP’18).

Positions

Roswell Park Comprehensive Cancer Center

  • Professor of Oncology & Vice Chair
  • Department of Biostatistics and Bioinformatics

Background

Education and Training:

  • BS - 2002 - University of Science and Technology of China
  • PhD - 2006 - State University of New York at Buffalo
  • Executive Education: General Management Program - Wharton School of Business, University of Pennsylvania

Fellowship:

  • Post-doctoral Fellow - Howard Hughes Medical Institute (HHMI) at Columbia University

Professional Memberships:

  • American Association for Cancer Research (AACR)
  • Society for Immunotherapy of Cancer (SITC)

Research

Research Overview:

I am a Professor and Vice Chair of the Department of Biostatistics and Bioinformatics at Roswell Park Comprehensive Cancer Center. My research revolves around the development and application of computational methods to address biologically important and clinically significant questions in cancer diagnosis and treatment.

I am currently one of the Principal Investigators of the Data Management and Resource-Sharing Center for the Immuno-Oncology Translational Network (IOTN), an NCI-funded Cancer Moonshot flagship initiative devoted to cancer immunotherapy. I am also one of the Principal Investigators of the Coordination Center for the Drug Resistance and Sensitivity Network (DRSN), an NCI-funded Cancer Moonshot flagship initiative devoted to innovative strategies to understand and combat mechanisms of tumor resistance and to exploit tumor sensitivity to anti-cancer therapies.

I am the founding director of the Roswell Park CCSG Bioinformatics Core. I co-lead the Biostatistics and Bioinformatics Core of an NCI-funded Cancer Immunotherapy P01 Program, which focuses on targeting the chemokine system to sensitize tumors to immunotherapy.

I am the author of more than 200 peer-reviewed publications, which have been cited over 10,000 times. I am an Associate Editors-in-Chief of Genomics, Proteomics & Bioinformatics (GPB).


Publications

Full Publications list on PubMed

CD8+ T cell immunity blocks the metastasis of carcinogen-exposed breast cancer. Li K, Li T, Feng Z, Huang M, Wei L, Yan Z, Long M, Hu Q, Wang J, Liu S, Sgroi DC, Demehri S. Science Advances 2021 Jun 18;7(25):eabd8936.

Bioconductor toolchain for reproducible bioinformatics pipelines using Rcwl and RcwlPipelines. Hu Q, Hutson A, Liu S, Morgan M, Liu Q. Bioinformatics. 2021 Mar 27:btab208. doi: 10.1093/bioinformatics/btab208.

MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer. Yamashita N, Long M, Fushimi A, Yamamoto M, Hata T, Hagiwara M, Bhattacharya A, Hu Q, Wong KK*, Liu S*, Kufe D*. Journal for ImmunoTherapy of Cancer. 2021;9(1):e002115.

RNA Dysregulation: An Expanding Source of Cancer Immunotherapy Targets. Pan Y, Kadash-Edmondson K, Wang R, Phillips J, Liu S, Ribas A, Aplenc R, Witte O, Xing Y. Trends in Pharmacological Sciences 2021; 42(4), 268-282.

Efficacy and Safety of Pembrolizumab in Combination with Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial. Zsiros E, Lynam S, Attwood KM, Wang C, Chilakapati S, Gomez EC, Liu S, Akers S, Lele S, Frederick PJ, Odunsi K. JAMA Oncology 2021;7(1):78-85.

Activation of NF-κB and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation. Zhou Y, Bastian IN, Long MD, Dow M, Li W, Liu T, Ngu RK, Antonucci L, Huang JY, Phung QT, Zhao XH, Banerjee S, Lin XJ, Wang H, Dang B, Choi S, Karin D, Su H, Ellisman MH, Jamieson C, Bosenberg M, Cheng Z, Haybaeck J, Kenner L, Fisch KM, Bourgon R, Hernandez G, Lill JR, Liu S, Carter H, Mellman I, Karin M, Shalapour S. Proceedings of the National Academy of Sciences. 2021;118(8):e2025840118.

Ultradeep sequencing differentiates patterns of skin clonal mutations associated with sun-exposure status and skin cancer burden. Wei L, Christensen SR, Fitzgerald ME, Graham J, Hutson ND, Zhang C, Huang Z, Hu Q, Zhan F, Xie J, Zhang J, Liu S, Remenyik E, Gellen E, Colegio OR, Bax M, Xu J, Lin H, Huss WJ, Foster BA, Paragh G. Science Advances 2021 Jan 1;7(1):eabd7703.

Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction. Wells DK, van Buuren MM, Dang KK, Hubbard-Lucey VM, Sheehan KCF, Campbell KM, Lamb A, Ward JP, Sidney J, Blazquez AB, Rech AJ, Zaretsky JM, Comin-Anduix B, Ng A, Chour W, Yu TV, Rizvi H, Chen JM, Manning P, Steiner GM, Doan XC, Tumor Neoantigen Selection Alliance; Merghoub T, Guinney J, Kolom A, Selinsky C, Ribas A, Hellmann MD, Hacohen N, Sette A, Heath JR, Bhardwaj N, Ramsdell F, Schreiber RD, Schumacher TN, Kvistborg P, Defranoux NA. Cell 2020;183(3):818-834.e13.  

Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s. Oba T, Long MD, Keler T, Marsh HC, Minderman H, Abrams SI*, Liu S*, Ito F. Nature Communications 2020;11(1):5415.

Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer. Zhang D, Hu Q, Liu X, Ji Y, Chao HP, Liu Y, Tracz A, Kirk J, Buonamici S, Zhu P, Wang J, Liu S*, Tang DG*. Nature Communications 2020;11(1):2089

Pathway-guided analysis identifies Myc-dependent alternative pre-mRNA splicing in aggressive prostate cancers. Phillips JW, Pan Y, Tsai BL, Xie Z, Demirdjian L, Xiao W, Yang HT, Zhang Y, Lin CH, Cheng D, Hu Q, Liu S, Black DL, Witte ON, Xing Y. Proceedings of the National Academy of Sciences 2020;117(10):5269-5279.